<DOC>
	<DOCNO>NCT01287117</DOCNO>
	<brief_summary>The study global Phase III , multicenter , randomize , double-blind , placebo-controlled , parallel-group study evaluate efficacy safety omalizumab administer subcutaneously add-on therapy treatment adolescent adult patient age 12-75 diagnose refractory CIU remain symptomatic despite standard-dose H1 antihistamine treatment .</brief_summary>
	<brief_title>A Study Efficacy Safety Omalizumab ( Xolair ) Patients With Chronic Idiopathic Urticaria ( CIU ) /Chronic Spontaneous Urticaria ( CSU ) Who Remain Symptomatic Despite Antihistamine ( H1 ) Treatment</brief_title>
	<detailed_description>Type I Error Rate Control Plan Primary Outcome Measure In order maintain overall type I error rate 0.05 ( 2-sided ) across 3 omalizumab dose level , test primary Outcome Measure conduct follow hierarchical order . A p-value &lt; 0.05 consider statistically significant statistical significance claim previous stage . - Stage 1 : Omalizumab 300-mg group vs. placebo - Stage 2 : Omalizumab 150-mg group vs. placebo - Stage 3 : Omalizumab 75-mg group vs. placebo Secondary Outcome Measures A hierarchical analysis follow secondary Outcome Measures perform dose find significant primary Outcome Measure . A p-value &lt; 0.05 consider statistically significant statistical significance claim previous stage . - Stage 1 : Change baseline Week 12 urticaria activity score 7 day ( UAS7 ) - Stage 2 : Change Baseline Week 12 weekly number hive score - Stage 3 : Time minimally important difference ( MID ) response weekly itch severity score Week 12 - Stage 4 : Percentage participant UAS7 score â‰¤ 6 Week 12 - Stage 5 : Percentage weekly itch severity score MID responder Week 12 - Stage 6 : Change Baseline Week 12 weekly size large hive score - Stage 7 : Change Baseline overall dermatology life quality index ( DLQI ) score Week 12 - Stage 8 : Change Baseline overall dermatology life quality index ( DLQI ) score Week 12 - Stage 9 : Percentage complete responder ( UAS7 = 0 ) Week 12</detailed_description>
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Histamine Antagonists</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<criteria>Diagnosis Chronic Idiopathic Urticaria ( CIU ) /Chronic Spontaneous Urticaria ( CSU ) refractory H1 antihistamine time randomization . Treatment investigational agent within 30 day prior screen . Weight &lt; 20 kg ( 44 lb ) . Clearly define underlying etiology chronic urticarias CIU . Evidence parasitic infection . Atopic dermatitis , bullous pemphigoid , dermatitis herpetiformis , senile pruritus , skin disease associate itch . Previous treatment omalizumab within year prior screen . Routine dos follow medication within 30 day prior screen : Systemic cutaneous ( topical ) corticosteroid ( prescription counter ) , hydroxychloroquine , methotrexate , cyclosporine , cyclophosphamide . Intravenous ( IV ) immunoglobulin G ( IVIG ) , plasmapheresis within 30 day prior screen . Regular ( daily/every day ) doxepin ( oral ) use within 6 week prior screen . Any H2 antihistamine use within 7 day prior screen . Any leukotriene receptor antagonist ( LTRA ) ( montelukast zafirlukast ) within 7 day prior screen . Any H1 antihistamine great approve dos within 3 day prior screen . Patients current malignancy , history malignancy , currently workup suspect malignancy except nonmelanoma skin cancer treat excise consider resolve . Hypersensitivity omalizumab component formulation . History anaphylactic shock . Presence clinically significant cardiovascular , neurological , psychiatric , metabolic , pathological condition could interfere interpretation study result compromise safety patient . Evidence current drug alcohol abuse . Nursing woman woman childbearing potential , unless meet follow definition postmenopausal : 12 month natural amenorrhea 6 month spontaneous amenorrhea serum folliclestimulating hormone ( FSH ) level &gt; 40 mIU/mL 6 week post surgical bilateral oophorectomy ( without hysterectomy ) hysterectomy use one follow acceptable method contraception : surgical sterilization , hormonal contraception , doublebarrier method .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>